Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-alcoholic Steatohepatitis (NASH): early-phase trial registry
2 of 17 indexed Non-alcoholic Steatohepatitis (NASH) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 2 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Non-alcoholic Steatohepatitis (NASH): 17 US clinical trials tracked, 2 recruiting.
Non-alcoholic Steatohepatitis (NASH) is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is Corcept Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition non-alcoholic-steatohepatitis-nash
OPEN 2 | RECR 12% | LATE 1 | EARLY 11 | RANK #1004 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Gestational Diabetes Mellitus (12% recruiting · 17 trials)
Non-alcoholic Steatohepatitis (NASH) lists 2 open slots (12% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-alcoholic Steatohepatitis (NASH) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-alcoholic Steatohepatitis (NASH) is recruiting below its size-band peers.
2 of 17 indexed trials (11.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Non-alcoholic Steatohepatitis (NASH) trials is spread across many organizations.
Corcept Therapeutics accounts for 2 of 17 trials (11.8%). 16 distinct sponsors appear on at least one study for this condition label.
-
Typical Non-alcoholic Steatohepatitis (NASH) enrolment sits around 120 participants.
Median target enrolment is 120 among the 17 trials that report a genuine target (sentinel values excluded). 7 of those (41.2%) plan for fewer than 100 participants.
-
Non-alcoholic Steatohepatitis (NASH) research is mostly interventional.
15 interventional and 2 observational studies make up this index (88.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
Blood Collection Biorepository for Liver Disease Research
State University of New York at Buffalo
NCT03025074
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Corcept Therapeutics
NCT06947304
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
Corcept Therapeutics
NCT06108219
Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study
University of California, Davis
NCT02754037
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
Hepion Pharmaceuticals
NCT05402371
A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)
Brigham and Women's Hospital
NCT04820036
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT01265498
A Phase 2b Study of Icosabutate in Fatty Liver Disease
NorthSea Therapeutics B.V.
NCT04052516
Phase 2b Study in NASH to Assess IVA337
Inventiva Pharma
NCT03008070
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight
Boehringer Ingelheim
NCT06309992
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
Altimmune
NCT05989711
A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis
Immuron
NCT02316717
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH
Cascade Pharmaceuticals
NCT05591079
A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
AstraZeneca
NCT04483947
Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3
Gilead Sciences
NCT02466516
Tesamorelin Effects on Liver Fat and Histology in HIV
Massachusetts General Hospital
NCT02196831
Feasibility of VIIT in Adults With NASH
Duke University
NCT03861819
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 9 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-alcoholic Steatohepatitis (NASH) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-alcoholic Steatohepatitis (NASH) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-alcoholic Steatohepatitis (NASH) page
17 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Non-alcoholic Steatohepatitis (NASH) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Corcept Therapeutics sponsors the most Non-alcoholic Steatohepatitis (NASH) trials on record, review their full trial history before evaluating a specific study. See Corcept Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-alcoholic Steatohepatitis (NASH) condition card totals 17 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.